A Phase 1b/2a Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of PB-718, a GLP-1R/GCGR Dual Agonist in Subjects with Obesity

被引：0
|
作者：
Ding, Ke
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-768-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
768-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetics and Pharmacodynamic Effects of a Single Dose of the Long-Acting GLP-1R Agonist LAPS-Exendin-4 in Subjects With Type 2 Diabetes Mellitus
    Kim, Yung I.
    Kim, Sei-Eun
    Choi, In Young
    Bae, Sungmin
    Lee, Kyu Hwang
    Park, Kyung-Mi
    Kang, Jahoon
    Kwon, Se Chang
    Son, Jeewoong
    DIABETES, 2012, 61 : A277 - A277
  • [32] A Phase 1b/2a Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Nano-Genistein and Chemoradiotherapy for Non-Small Cell Lung Cancer
    Kaytor, M. D.
    Brown, S. L.
    Arapi, I.
    Kurman, M.
    Dykstra, J. C.
    Rillo, L.
    Ingram, M.
    Poppitz, S.
    Menon, S.
    Thompson, J.
    Wang, D.
    Ajlouni, M.
    Gore, E. M.
    Movsas, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E688 - E688
  • [33] Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial
    Ji, Linong
    Gao, Leili
    Jiang, Hongwei
    Yang, Jing
    Yu, Lei
    Wen, Jie
    Cai, Chenghang
    Deng, Huan
    Feng, Liqi
    Song, Baili
    Ma, Qingyang
    Qian, Lei
    ECLINICALMEDICINE, 2022, 54
  • [34] A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema
    Brigell, Mitchell G.
    Campochiaro, Peter A.
    Sophie, Raafay
    Tolentino, Michael
    Miller, Daniel
    Browning, David
    Boyer, David S.
    Heier, Jeffrey S.
    Peters, Kevin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [35] A phase 1/2a study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies
    Wilson, Wyndham H.
    Tulpule, Anil
    Levine, Alexandra M.
    Dunleavy, Kieron
    Krivoshik, Andrew P.
    Hagey, Anne E.
    Shovlin, Margaret
    Gloria, Melanie A.
    Greco, Renee
    Xiong, Hao
    Chiu, Yi-Lin
    Elmore, Steven W.
    O'Connor, Owen A.
    BLOOD, 2007, 110 (11) : 412A - 412A
  • [36] A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale
    Santa Gadea, Omar Saavedra
    Garralda, Elena
    Suzanne Lopez, Juanita
    Awad, Mark M.
    Stephen Thomas, Jacob
    Diane Tiu, Crescens
    Morales-Espinosa, Daniela
    Raab, Christa
    Rehbein, Bettina
    Hintzen, Gabriele
    Pietzko, Kerstin
    Ravenstijn, Paulien
    Emig, Michael
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [37] Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity-A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial
    Aronne, Louis
    Harris, M. Scott
    Roberts, M. S.
    Suschak, John J.
    Tomah, Shaheen
    Kasper, Jonathan
    He, Liang
    Yang, Jay
    Frias, Juan P.
    Browne, Sarah K.
    DIABETES, 2024, 73
  • [38] Safety and Efficacy ATYR1923, a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
    Sporn, P. H.
    Culver, D. A.
    Barney, J.
    Maier, L. A.
    James, W. E.
    Hsia, C. C. W.
    Sweiss, N. J.
    Aryal, S.
    Obi, O. N.
    Tabassomi, M.
    Marts, L. T.
    Walker, G.
    Carey, L.
    Shukla, S.
    Baughman, R. P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [39] Dapiglutide, a Once-Weekly GLP-1R/GLP-2R Dual Agonist, Was Safe and Well Tolerated and Showed Dose-Dependent Body Weight Loss over Four Weeks in Healthy Subjects
    Olsen, Minna B.
    Hovelmann, Ulrike
    Griffin, Jon
    Knudsen, Kim M.
    Eriksson, Per-Olof
    Agersnap, Mikkel A.
    DIABETES, 2022, 71
  • [40] Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects
    Vandell, Alexander G.
    Inoue, Satoshi
    Dennie, Justin
    Nagasawa, Yasuo
    Gajee, Roohi
    Pav, Joe
    Zhang, George
    Zamora, Cynthia
    Masuda, Nobuhisa
    Senaldi, Giorgio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (05)
12345